Education
About Us
Working with TipRanks
Follow Us
Merck & Company (DE:6MK)
XETRA:6MK
6MK Stock Chart & Stats
Day’s Range― - ―
52-Week Range€65.50 - €105.80
Previous CloseN/A
Volume75.00
Average Volume (3M)2.52K
Market Cap
$172.10B
Enterprise Value€225.73B
Total Cash (Recent Filing)$8.62B
Total Debt (Recent Filing)$35.40B
Price to Earnings (P/E)11.6
Beta0.43
Next Earnings
Oct 30, 2025EPS Estimate
2.01Last Dividend Ex-Date
Sep 15, 2025Dividend Yield4.17%
Share Statistics
EPS (TTM)1.81
Shares Outstanding2,497,783,200
10 Day Avg. Volume4,252
30 Day Avg. Volume2,519
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.44
Price to Sales (P/S)3.93
P/FCF Ratio13.92
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit4.63
Enterprise Value/Ebitda9.02
Forecast
1Y Price Target
$84.65Price Target Upside22.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Business OptimizationThe newly announced $3bn optimization initiative is viewed as a sensible re-allocation of capital from slower growth areas to fund new launches and R&D.
Growth PotentialMerck's strong Phase 2 update for I-DXd supports accelerated approval in extensive-stage small cell lung cancer, providing a significant first-to-market advantage over competitors.
Product InnovationPerformance from the company’s key new product cycle, Winrevair, remains intact with optimism on potential label expansion and data from the HYPERION trial.
Bears Say
Clinical Trial DelaysUncertainty on the timing of the Ph2 CADENCE trial data presentation for Winreviar, affecting what was viewed as a key clinical catalyst.
Market And Demand UncertaintyPersisting uncertainty on the Gardisal franchise in both China and increasingly in the US due to lumpy CDC purchasing patterns and potential for lower dosing regimens.
Patent Expiry ConcernsValuation discount reflects uncertainty around growth profile, with error bars on Merck’s long-term sales profile remaining large and the Keytruda patent expiry looming.
Merck & Company News
6MK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was €65.50 and its highest was €105.80 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $172.10B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 30, 2025 which is in 41 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2025. The company reported €1.809 earnings per share for the quarter, beating the consensus estimate of €1.726 by €0.082.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of €0.684 which represents an annual dividend yield of 4.17%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.01.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,497,783,200 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of €1.809 in its last earnings report, beating expectations of €1.726. Following the earnings report the stock price went up 3.148%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in DE:6MK
Merck & Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$84.65 (22.86% Upside)
$84.65 (22.86% Upside)
Blogger Sentiment
Bullish
DE:6MK Sentiment 90%
Sector Average 73%
Sector Average 73%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.73%
12-Months-Change
Fundamentals
Return on Equity
35.44%
Trailing 12-Months
Asset Growth
4.34%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
6MK Company Deck
6MK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted Merck's strong performance with new product launches and a robust pipeline, particularly in oncology and cardiopulmonary. However, challenges in China with GARDASIL and competitive pressures from biosimilars were notable lowlights.View all DE:6MK earnings summaries6MK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
6MK Stock 12 Month Forecast
Average Price Target
€84.65
▲(22.86% Upside)
Technical Analysis
Options Prices
Currently, No data available
---